Current Problems in Cardiology
Volume 34, Issue 9 , Pages 359-476 , September 2009

Endovascular Treatment of Peripheral Vascular Disease

References 

  1. Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: Cross-sectional study. Atherosclerosis. 2004;172:95–105
  2. Zheng ZJ, Sharrett AR, Chambless LE, et al. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: The atherosclerosis risk in communities (ARIC) study. Atherosclerosis. 1997;131:115–125
  3. Fowkes FGR, Housley E, Cawood EHH, et al. Edinburgh Artery Study Prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991;20:384–392
  4. Newman AB, Sutton-Tyrrell K, Rutan GH, et al. Lower extremity arterial disease in elderly subjects with systolic hypertension. J Clin Epidemiol. 1991;44:15–20
  5. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381–386
  6. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology, Society for Vascular Medicine and Biology and The American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease). J Am Coll Cardiol. 2006;47:1239–1312
  7. Newman AB, Shemanski L, Manolio TA, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the cardiovascular health study. Arterioscler Thromb Vasc Biol. 1999;19:538–545
  8. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (Caprie). Lancet. 1996;348:1329–1339
  9. Baumgartner I, Hirsch AT, Abola TB, et al. Cardiovascular risk profile and outcome of patients with abdominal aortic aneurysm in out-patients with atherothrombosis: Data from the Reduction Of Atherothrombosis For Continued Health (REACH) Registry. J Vasc Surg. 2008;48:808–813
  10. Fowkes FG, Low LP, Tuta S, et al. AGATHA Investigators Ankle brachial index and the extent of atherothrombosis in 8891 patients with or at risk of vascular disease: Results of the international AGATHA study. Eur Heart J. 2006;27:1861–1867
  11. Criqui MH, Denenberg JO, Langer RD, et al. The epidemiology of peripheral arterial disease: Importance of identifying the population at risk. Vasc Med. 1997;2:221–226
  12. Price JF, Mowbray PI, Lee AJ, et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh artery study. Eur Heart J. 1999;20:344–353
  13. Barani J, Nilsson JA, Matiasson I, et al. Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. J Vasc Surg. 2005;42:75–80
  14. McDermott MM, Greenland P, Guralnik JM, et al. Depressive symptoms and lower extremity functioning in men and women with peripheral arterial disease. J Gen Intern Med. 2003;18:461–467
  15. McDermott MM, Liu K, Greenland P, et al. Functional decline in peripheral arterial disease: Associations with the ankle brachial index and leg symptoms. J Am Med Assoc. 2004;292:453–461
  16. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. J Am Med Assoc. 2001;286:1317–1324
  17. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(suppl):S5–S67
  18. Dormandy JA, Murray GD. The fate of the claudicant: A prospective study of 1969 claudicants. Eur J Vasc Surg. 1991;5:131–133
  19. Jelnes R, Gaardsting O, Hougaard Jensen K, et al. Fate in intermittent claudication: Outcome and risk factors. Br Med J. 1986;293:1137–1140
  20. Belch JJ, Topol EJ, Agnelli G, et al. Prevention of Atherothrombotic Disease Network (Critical issues in peripheral arterial disease detection and management: A call to action). Arch Intern Med. 2003;163:884–892
  21. Dormandy JA, Heeck L, Vig S. The fate of patients with critical leg ischemia. Semin Vasc Surg. 1999;12:142–147
  22. DeGowin R, DeGowin E. The blood vessels/circulation of limbs. In:  DeGowin EL,  DeGowin RL editor. DeGowin And DeGowin'S Bedside Diagnostic Examination. 5th edition. New York, NY: Macmillan; 1987;p. 415–466
  23. Woods BO. Clinical evaluation of the peripheral vasculature. Cardiol Clin. 1991;9:413–427
  24. Ouriel K, McDonnell AE, Metz CE, et al. Critical evaluation of stress testing in the diagnosis of peripheral vascular disease. Surgery. 1982;91:686–693
  25. Baxter GM, Polak JF. Lower limb colour flow imaging: A comparison with ankle: Brachial measurements and angiography. Clin Radiol. 1993;47:91–95
  26. Doobay AV, Anand SS. Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: A systematic review. Arterioscler Thromb Vasc Biol. 2005;25:1463–1469
  27. Newman AB, Siscovick DS, Manolio TA, et al. Cardiovascular Health Study (CHS) Collaborative Research Group Ankle-arm index as a marker of atherosclerosis in the cardiovascular health study. Circulation. 1993;88:837–845
  28. Sumner DS, Strandness DE. The relationship between calf blood flow and ankle blood pressure in patients with intermittent claudication. Surgery. 1969;65:763–771
  29. Olin JW. Clinical evaluation and office-based detection of peripheral arterial disease. Society for Vascular Medicine and Biology and Society for Vascular Nursing. Peripheral Arterial Disease: Marker of Cardiovascular Risk. Manchester, Mass: SVMB/SVM; 1999. http://www.svmb.org/medpro/cme/pl/cme_partl.html (accessed November 2, 2000).
  30. Sacks D, Bakal CW, Beatty PT, et al. Position statement on the use of the ankle-brachial index in the evaluation of patients with peripheral vascular disease: A consensus statement developed by the standards division of the Society of Cardiovascular and Interventional Radiology. J Vasc Interv Radiol. 2002;13:353
  31. Resnick HE, Lindsay RS, McDermott MM, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: The strong heart study. Circulation. 2004;109:733–739
  32. Collins R, Armitage J, Parish S, et al. Heart Protection Study Collaborative Group MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals (A randomised placebo-controlled trial). Lancet. 2002;360:7–22
  33. Feringa HH, Karagiannis SE, van Waning VH, et al. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. J Vasc Surg. 2007;45:936–943
  34. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation. 2003;107:1848–1851
  35. Schillinger M, Exner M, Mlekusch W, et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J. 2004;25:742–748
  36. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain (A meta-analysis). J Am Med Assoc. 1995;274:975–980
  37. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: Meta-analysis of randomized controlled trials. CMAJ. 1996;155:1053
  38. Regensteiner JG, Ware JE, McCarthy WJ, et al. Effect of cilostazol on treadmill walking, community based walking ability and health related quality of life in patients with intermittent claudication due to peripheral arterial disease: Metaanalysis of six randomized controlled trials. J Am Geriatr Soc. 2002;50:1939–1946
  39. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325:445–453
  40. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study (ACAS). Endarterectomy for asymptomatic carotid artery stenosis. J Am Med Assoc. 1995;273:1421–1428
  41. Biller J, Feinberg WM, Castaldo JE, et al. Guidelines for carotid endarterectomy (AHA scientific statement). Circulation. 1998;97:501–509
  42. Yadav JS, Roubin GS, Iyer S, et al. Elective stenting of the extracranial carotid arteries. Circulation. 1997;95:376–381
  43. Wholey MH, Wholey M, Mathias K, et al. Global experience in cervical carotid artery stent placement. Catheter Cardiovasc Interv. 2000;50:160–167
  44. Lin PH, Bush RL, Peden EK, et al. Carotid artery stenting with neuroprotection: Assessing the learning curve and treatment outcome. Am J Surg. 2005;190:850–857
  45. Mathias KD. Angioplasty and stenting for carotid lesions. Adv Surg. 2002;32:225–243
  46. Cremonesi A, Manetti R, Setacci F, et al. Protected carotid stenting: Clinical advantages and complications of embolic protection devices in 442 consecutive patients. Stroke. 2003;34:1936–1941
  47. Ribo M, Molina CA, Alvarez B, et al. Transcranial Doppler monitoring of transcervical carotid stenting with flow reversal protection: A novel carotid revascularization technique. Stroke. 2006;37:2846–2849
  48. Ohki T. The dark side of embolic protection devices. Endovasc Today. 2003;9:111–119
  49. Reimers B, Corvaja N, Moshiri S, et al. Cerebral protection with filter devices during carotid artery stenting. Circulation. 2001;104:12–15
  50. Yadav JS, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med. 2004;351:1493–1501
  51. Gurm HS, Yadav JS, Fayad P, et al. Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med. 2008;358:1572–1579
  52. Harjai KJ, Mehta RH. Trials and tribulations of carotid artery stenting: The interventionalists' perspective on sapphire, EVA-3S, and SPACE trials. J Interv Cardiol. 2007;20:389–394
  53. Mas JL, Chatellier G, Beyssen B, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med. 2006;355:1660–1671
  54. Mas JL, Trinquart L, Leys D, et al. Endarterectomy versus angioplasty in patients with symptomatic severe carotid stenosis (EVA-3S) trial: Results up to 4 years from a randomized, multicenter trial. Lancet Neurol. 2008;7:885–892
  55. Ringleb PA, Allenberg J, Berger J, et al. SPACE Collaborative Group 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients (A randomised non-inferiority trial). Lancet. 2006;368:1239–1247
  56. Eckstein HH, Ringleb P, Allenberg JR, et al. Results of the stent-protected angioplasty versus carotid endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: A multinational, prospective, randomised trial. Lancet Neurol. 2008;7:893–902
  57. Roubin GS, Iyer S, Halkin A, et al. Realizing the potential of carotid artery stenting: Proposed paradigms for patient selection and procedural technique. Circulation. 2006;113:2021–2030
  58. Peel G, Wholey MH, Hagino RT, et al. Percutaneous carotid artery intervention: A word of caution about mixing stent/filter systems. J Endovasc Ther. 2007;14:110–112
  59. Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: The clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (caress) trial. Circulation. 2005;111:2233–2240
  60. White CJ, Iyer SS, Hopkins LN, et al. BEACH Trial Investigators Carotid stenting with distal protection in high surgical risk patients: The BEACH trial 30 day results. Catheter Cardiovasc Interv. 2006;67:503–512
  61. Iyer SS, White CJ, Hopkins LN, et al. Carotid artery revascularization in high-surgical-risk patients using the carotid WALLSTENT and FilterWire ex/EZ: 1-year outcomes in the BEACH pivotal group. J Am Coll Cardiol. 2008;51:427–434
  62. White RA, Diethrich E, Fogarty TJ, et al. CaRESS Steering Committee Carotid revascularization using endarterectomy or stenting systems (CaRESS) Phase I clinical trial: 1-year results. J Vasc Surg. 2005;42:213–219
  63. Sugita J, Cremonesi A, Van Elst F, et al. European carotid PROCAR trial: Prospective multicenter trial to evaluate the safety and performance of the ev3 protégé stent in the treatment of carotid artery stenosis—1- and 6-month follow-up. J Interv Cardiol. 2006;19:215–221
  64. Gray WA, Yadav JS, Verta P, et al. The CAPTURE registry: Results of carotid stenting with embolic protection in the post approval setting. J Vasc Surg. 2005;42:213–219
  65. Gray WA, Yadav JS, Verta P, et al. The CAPTURE registry: Results of carotid stenting with embolic protection in the post approval setting. Catheter Cardiovasc Interv. 2007;69:341–348
  66. Safian RD, Bresnahan JF, Jaff MR, et al. Protected carotid stenting in high-risk patients with severe carotid artery stenosis. J Am Coll Cardiol. 2006;47:2384–2389
  67. Katzen BT, Criado FJ, Ramee SR, et al. Carotid artery stenting with emboli protection surveillance study: Thirty-day results of the CASES-PMS study. Catheter Cardiovasc Interv. 2007;70:316–323
  68. Berguer R, Flynn LM, Kline RA, et al. Surgical reconstruction of the extracranial vertebral artery: Management and outcome. J Vasc Surg. 2000;31:9–18
  69. Jenkins JS, White CJ, Ramee SR, et al. Vertebral artery stenting. Catheter Cardiovasc Interv. 2001;54:1–5
  70. Malek AM, Higashida RT, Phatouros CC, et al. Treatment of posterior circulation ischemia with extracranial percutaneous balloon angioplasty and stent placement. Stroke. 1999;30:2073–2085
  71. Beebe HG, Stark R, Johnson ML, et al. Choices of operation for subclavian vertebral arterial disease. Am J Surg. 1980;139:616–623
  72. Hadjipetrou P, Cox S, Piemonte T, et al. Percutaneous revascularization of atherosclerotic obstruction of aortic arch vessels. J Am Coll Cardiol. 1999;33:1238–1245
  73. Rodriguez-Lopez JA, Werner A, Martinez R, et al. Stenting for atherosclerotic occlusive disease of the subclavian artery. Ann Vasc Surg. 1999;13:254–260
  74. Al-Mubarak N, Liu MW, Dean LS, et al. Immediate and late outcomes of subclavian artery stenting. Catheter Cardiovasc Interv. 1999;46:169–172
  75. Jain SP, Zhang SY, Khosla S, et al. Subclavian and innominate arteries stenting: Acute and long term results. J Am Coll Cardiol. 1998;31:63A
  76. Jean WJ, Al-bitar I, Zwicke DL, et al. High incidence of renal artery stenosis in patients with coronary artery disease. Catheter Cardiovasc Interv. 1994;32:8–10
  77. Weber-Mzell D, Kotanko P, Schumacher M, et al. Coronary anatomy predicts presence or absence of renal artery stenosis (A prospective study in patients undergoing cardiac catheterization for suspected coronary artery disease). Eur Heart J. 2002;23:1684–1691
  78. Buller CE, Nogareda JG, Ramanathan K, et al. The profile of cardiac patients with renal artery stenosis. J Am Coll Cardiol. 2004;43:1606–1613
  79. Caps MT, Perissinotto C, Zierler RE, et al. Prospective study of atherosclerotic disease progression in the renal artery. Circulation. 1998;98:2866–2872
  80. Caps MT, Zierler RE, Polissar NL, et al. Risk of atrophy in kidneys with atherosclerotic renal artery stenosis. Kidney Int. 1998;53:735–742
  81. Hansen KJ, Starr SM, Sands RE, et al. Contemporary surgical management of renovascular disease. J Vasc Surg. 1991;16:319–331
  82. Textor SC. Renovascular hypertension in 2007: Where are we now?. Curr Cardiol Rep. 2007;9:453–461
  83. Welch WJ, Mendonca M, Aslam S, et al. Roles of oxidative stress and AT1 receptors in renal hemodynamics and oxygenation in the postclipped 2K,1C kidney. Hypertension. 2003;41:692–696
  84. Parildar M, Parildar Z, Oran I, et al. Nitric oxide and oxidative stress in atherosclerotic renovascular hypertension: Effects of endovascular treatment. J Vasc Interv Radiol. 2003;14:887–892
  85. Balk E, Raman G, Chung M, et al. Effectiveness of management strategies for renal artery stenosis: A systematic review. Ann Intern Med. 2006;145:901–912
  86. Silva JA, Chan AW, White CJ, et al. Elevated brain natriuretic peptide predicts blood pressure response after stent revascularization in patients with renal artery stenosis. Circulation. 2005;111:328–333
  87. Mitchell JA, Subramanian R, White CJ, et al. Predicting blood pressure improvement in hypertensive patients after renal artery stent placement: Renal fractional flow reserve. Catheter Cardiovasc Interv. 2007;69:685–689
  88. Kidney D, Deutsch LS. The indications and results of percutaneous transluminal angioplasty and stenting in renal artery stenosis. Semin Vasc Surg. 1996;9:188–197
  89. Lederman RJ, Mendelsohn FO, Santos R, et al. Primary renal artery stenting: Characteristics and outcomes after 363 procedures. Am Heart J. 2001;142:314–323
  90. Burket MW, Cooper CJ, Kennedy DJ, et al. Renal artery angioplasty and stent placement: Predictors of a favorable outcome. Am Heart J. 2000;139:64–71
  91. Rodriguez-Lopez JA, Werner A, Ray LI, et al. Renal artery stenosis treated with stent deployment: Indications, technique, and outcome for 108 patients. J Vasc Surg. 1999;29:617–624
  92. Rocha-Singh KJ, Mishkel G, Katholi RE, et al. Clinical predictors of improved long-term blood pressure control after successful stenting of hypertensive patients with obstructive renal artery atherosclerosis. Catheter Cardiovasc Interv. 1999;47:167–172
  93. Dorros G, Jaff M, Mathiak L, et al. Four-year follow-up of Palmaz-Schatz Stent revascularization as treatment for atherosclerotic renal artery stenosis. Circulation. 1998;98:642–647
  94. White CJ, Ramee SR, Collins TJ, et al. Renal artery stent placement: Utility in lesions difficult to treat with balloon angioplasty. J Am Coll Cardiol. 1997;30:1445–1450
  95. Allaqaband S, Shaikh F, Zaidi S, et al. Blood pressure control after renal artery stenting in 100 consecutive hypertensive patients with atherosclerotic renal artery stenosis. Am J Cardiol. 2003;92:53L
  96. Dorros G, Jaff M, Mathiak L, et al. Multicenter PALMAZ stent renal artery stenosis revascularization registry report: Four-year follow-up of 1058 successful patients. Catheter Cardiovasc Interv. 2002;55:182–188
  97. Rocha-Singh K, Jaff MR, Rosenfield K Aspire-2 Trial Investigators. evaluation of the safety and effectiveness of renal artery stenting after unsuccessful balloon angioplasty: The aspire-2 study. J Am Coll Cardiol. 2005;46:776–783
  98. Mistry S, Ives N, Harding J, et al. Angioplasty and stent for renal artery lesions (ASTRAL trial): Rationale, methods, and results so far. J Hum Hypertens. 2007;21:511–515
  99. Rocha-Singh K, Jaff MR, Kelley EL, et al. Renal artery stenting with noninvasive duplex ultrasound follow-up: 3-year results from the RENAISSANCE renal stent trial. Catheter Cardiovasc Interv. 2008;72:853–862
  100. Cooper CJ, Murphy TP, Matsumoto A, et al. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: Rationale and design of the CORAL trial. Am Heart J. 2006;152:59–66
  101. Dubel GJ, Murphy TP. Distal embolic protection for renal arterial interventions. Cardiovasc Interv Radiol. 2008;31:14–22
  102. Cooper CJ, Haller ST, Coyler W, et al. Embolic protection and platelet inhibition during renal artery stenting. Circulation. 2008;117:2752–2760
  103. Holden A, Hill A, Jaff MR, et al. renal artery stent revascularization with embolic protection in patients with ischemic nephropathy. Kidney Int. 2006;70:948–955
  104. Edwards MS, Craven BL, Stafford J, et al. Distal embolic protection during renal artery angioplasty and stenting. J Vasc Surg. 2006;44:128–135
  105. Kougias P, El Sayed HF, Zhow W, et al. Management of chronic mesenteric ischemia (The role of endovascular therapy). J Endovasc Ther. 2007;14:395–405
  106. Herbert GS, Steele SR. Acute and chronic mesenteric ischemia. Surg Clin North Am. 2007;87:1115–1134
  107. Acosta S, Ogren M, Sternby NH, et al. Fatal nonocclusive mesenteric ischaemia: Population-based incidence and risk factors. J Intern Med. 2006;259(3):305–313
  108. Park WM, Cherry KJ, Chua HK, et al. Current results of open revascularization for chronic mesenteric ischemia: A standard for comparison. J Vasc Surg. 2002;35:853–859
  109. Sarac TP, Altinel O, Kashyap V, et al. Endovascular treatment of stenotic and occluded visceral arteries for chronic mesenteric ischemia. J Vasc Surg. 2008;47:485–491
  110. Silva JA, White CJ, Collins TJ, et al. Endovascular therapy for chronic mesenteric ischemia. J Am Coll Cardiol. 2006;47:944–950
  111. Brown DJ, Schermerhorn ML, Powell RJ, et al. Mesenteric stenting for chronic mesenteric ischemia. J Vasc Surg. 2005;42:268–274
  112. Landis MS, Rajan DK, Simons ME, et al. Percutaneous management of chronic mesenteric ischemia: Outcomes after intervention. J Vasc Interv Radiol. 2005;16:1319–1325
  113. Saeed A, Saeed A, Solis J, et al. Longevity of superior mesenteric artery stents. [abstract] JACC Cardiovascular Interventions. 2009;(in press)
  114. Sivamurthy N, Rhodes JM, Lee D, et al. Endovascular versus open mesenteric revascularization: Immediate benefits do not equate with short-term functional outcomes. J Am Coll Surg. 2006;202:859–867
  115. Lim RP, Dowling RJ, Thomson KR. Angioplasty and stenting of the superior mesenteric in acute mesenteric ischemia. Australas Radiol. 2004;48:426–429
  116. de Vries SO, Hunink MG. Results of aortic bifurcation grafts for aortoiliac occlusive disease: A meta-analysis. J Vasc Surg. 1997;26:558–569
  117. Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology. 1997;204:87–96
  118. d'Othee BJ, Haulon S, Mounier-Vehier C, et al. Percutaneous endovascular treatment for stenoses and occlusions of infrarenal aorta and aortoiliac bifurcation: Midterm results. Eur J Vasc Endovasc Surg. 2002;24:516–523
  119. Greiner A, Dessl A, Klein-Weigel P, et al. Kissing stents for treatment of complex aortoiliac disease. Eur J Vasc Endovasc Surg. 2003;26:161–165
  120. Greiner A, Muhlthaler H, Neuhauser B, et al. Does stent overlap influence the patency rate of aortoiliac kissing stents?. J Endovasc Ther. 2005;12:696–703
  121. Houston JG, Bhat R, Ross R, et al. Long-term results after placement of aortic bifurcation self-expanding stents: 10 year mortality, stent restenosis, and distal disease progression. Cardiovasc Interv Radiol. 2007;30:42–47
  122. Maynar M, Zander T, Qian Z, et al. Bifurcated endoprosthesis for treatment of aortoiliac occlusive lesions. J Endovasc Ther. 2005;12:22–27
  123. Mendelsohn FO, Santos RM, Crowley JJ, et al. Kissing stents in the aortic bifurcation. Am Heart J. 1998;136:600–605
  124. Mohamed F, Sarkar B, Timmons G, et al. Outcome of “Kissing stents” for aortoiliac atherosclerotic disease, including the effect on the non-diseased contralateral iliac limb. Cardiovasc Interv Radiol. 2002;25:472–475
  125. Piffaretti G, Tozzi M, Lomazzi C, et al. Mid-term results of endovascular reconstruction for aorto-iliac obstructive disease. Int Angiol. 2007;26(1):18–25
  126. Scheinert D, Schroder M, Balzer JO, et al. Stent-supported reconstruction of the aortoiliac bifurcation with the kissing balloon technique. Circulation. 1999;100:II295–II300(19)(suppl)
  127. Yilmaz S, Sindel T, Golbasi I, et al. Aortoiliac kissing stents: Long-term results and analysis of risk factors affecting patency. J Endovasc Ther. 2006;13:291–301
  128. Mouanoutoua M, Maddikunta R, Allaqaband S, et al. Endovascular intervention of aortoiliac occlusive disease in high-risk patients using the kissing stents technique: Long-term results. Catheter Cardiovasc Interv. 2003;60:320–326
  129. Ameli FM, Stein M, Provan JL, et al. Predictors of surgical outcome in patients undergoing aortobifemoral bypass reconstruction. J Cardiovasc Surg. 1990;30:333–339
  130. Johnston KW, Rae M, Hogg-Johnston SA, et al. 5-Year results of a prospective study of percutaneous transluminal angioplasty. Ann Surg. 1987;206:403–413
  131. Vorwerk D, Günther RW, Schürmann K, et al. Primary stent placement for chronic iliac artery occlusions: Follow-up results in 103 patients. Radiology. 1995;194:745–749
  132. Vorwerk D, Günther RW, Schürmann K, et al. Aortic and iliac stenoses: Follow-up results of stent placement after insufficient balloon angioplasty in 118 cases. Radiology. 1996;198:45–48
  133. Palmaz JC, Laborde JC, Rivera FJ, et al. Stenting of the iliac arteries with the Palmaz stent: Experience from a multicenter trial. Cardiovasc Interv Radiol. 1992;15:291–297
  134. Scheinert D, Schröder M, Ludwig J, et al. Stent-supported recanalization of chronic iliac artery occlusions. Am J Med. 2001;110:708–715
  135. Timaran CH, Ohki T, Gargiulo NJ, et al. Iliac artery stenting in patients with poor distal runoff: Influences of concomitant infrainguinal arterial reconstruction. J Vasc Surg. 2003;38:479–484
  136. Wilson SE, Wolf GL, Cross AP. Percutaneous transluminal angioplasty versus operation for peripheral arteriosclerosis: Report of a prospective randomized trial in a selected group of patients. J Vasc Surg. 1989;9:1–9
  137. Holm J, Arfvidsson B, Jivegard L, et al. Chronic lower limb ischaemia: A prospective randomised controlled study comparing the 1-year results of vascular surgery and percutaneous transluminal angioplasty (PTA). Eur J Vasc Surg. 1991;5:517–522
  138. Murphy TP, Ariaratnam NS, Carney WI, et al. Aortoiliac insufficiency: Long-term experience with stent placement for treatment. Radiology. 2004;231:243–249
  139. Park KB, Do YS, Kim JH, et al. Stent placement for chronic iliac arterial occlusive disease: The results of 10 years experience in a single institution. Korean J Radiol. 2005;6:256–266
  140. Henry M, Amor M, Ethevenot G, et al. Palmaz stent placement in iliac and femoropopliteal arteries: Primary and secondary patency in 310 patients with 2-4-year follow-up. Radiology. 1995;197:167–174
  141. Ponec D, Jaff MR, Swischuk J, et al. CRISP Study Investigators The nitinol SMART stent vs Wallstent for suboptimal iliac artery angioplasty: CRISP-US trial results. J Vasc Interv Radiol. 2004;15:911–918
  142. Wolf GL, Wilson SE, Cross AP, et al. Surgery or balloon angioplasty for peripheral vascular disease (A randomized clinical trial. Principal investigators and their Associates of Veterans Administration cooperative Study Number 199). J Vasc Interv Radiol. 1993;4:639–648
  143. Adam DJ, Beard JD, Cleveland T, et al. BASIL trial participants (bypass versus angioplasty in severe ischaemia of the leg (BASIL): Multicenter, randomszed controlled trial). Lancet. 2005;366:1925–1934
  144. Springhorn ME, Kinney M, Littooy FN, et al. Inflow atherosclerotic disease localized to the common femoral artery: Treatment and outcome. Ann Vasc Surg. 1991;5:234–240
  145. Mukherjee D, Inahara T. Endarterectomy as the procedure of choice for atherosclerotic occlusive lesions of the common femoral artery. Am J Surg. 1989;157:498–500
  146. Silva JA, White CJ, Quintana H, et al. Percutaneous revascularization of the common femoral artery for limb ischemia. Catheter Cardiovasc Interv. 2004;62:230–233
  147. Mahmud E, Keramati S, Salami A, et al. Expanded applications of rotational atherectomy in contemporary coronary and peripheral interventional practice. J Invasive Cardiol. 2005;17:207–210
  148. Silva JA, White CJ, Ranee SR, et al. Percutaneous profundoplasty in the treatment of lower extremity ischemia: Results of long-term surveillance. J Endovasc Ther. 2001;8:75–82
  149. Jacobs DL, Montaganahalli RL, Cox DE, et al. True lumen re-entry to facilitate subintimal angioplasty and stenting of total chronic occlusion. J Vasc Surg. 2006;43:1291–1296
  150. Lin S, Mckinsey JF. Plaque excision for the treatment of infrainguinal arterial occlusive disease. Tech Vasc Interv Radiol. 2005;8:165–168
  151. Scheinert D, Scheinert S, Sax J, et al. Prevalence of clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312–315
  152. Cejna M, Thurnher S, Illiasch H, et al. PTA v Palmaz Stent placement in femoropopliteal artery obstructions: A multicenter prospective randomized study. J Vasc Interv Radiol. 2001;12:23–31
  153. Zdanowski Z, Albrechtsson U, Lundin A, et al. Percutaneous transluminal angioplasty with or without stenting for femoropopliteal occlusions? (A randomized controlled study). Int Angiol. 1999;18:251–255
  154. Vroegindeweij D, Vos LD, Tielbeek AV, et al. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: A comparative randomized study. Cardiovasc Interv Radiol. 1997;20:420–425
  155. Zeller T, Tiefenbacher C, Steinkamp HJ, et al. Nitinol stent implantation in TASC A and B superficial femoral artery lesions: The femoral artery Conformexx trial (FACT). J Endovasc Ther. 2008;15:390–398
  156. Grimm J, Müller-Hulsbeck S, Jahnke T, et al. Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol. 2001;12:935–941
  157. Becquemin J-P, Favre J-P, Marzelle J. Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: A multicenter prospective randomized study. J Vasc Surg. 2003;37:487–494
  158. Henriksen LO, Jorgensen B, Holstein PE, et al. Percutaneous transluminal angioplasty of infrarenal arteries in intermittent claudication. Acta Chir Scand. 1988;154:573–576
  159. Krepel VM, van Andel GJ, van Erp WF, et al. Percutaneous transluminal angioplasty of the femoropopliteal artery: Initial and long-term results. Radiology. 1985;156:325–328
  160. Kandarpa K, Becker GJ, Hunink MG, et al. Transcatheter interventions for the treatment of peripheral atherosclerotic lesions (Part 1). J Vasc Interv Radiol. 2001;12:683–695
  161. Muradin GS, Bosch JL, Stijnen T, et al. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: Meta-analysis. Radiology. 2001;221:137–145
  162. Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: Six-month results. Circulation. 2002;106:1505–1509
  163. Sabeti S, Mlekusch W, Amighi J, et al. Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries. J Endovasc Ther. 2005;12:6–12
  164. Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: The sirocco II trial. J Vasc Interv Radiol. 2005;16:331–338
  165. Sabeti S, Schillinger M, Amighi J, et al. Primary patency of femoropopliteal arteries treated with nitinol versus stainless steel self-expanding stents: Propensity score-adjusted analysis. Radiology. 2004;232:516–521
  166. Lugmayr HF, Holzer H, Kastner M, et al. Treatment of complex arteriosclerotic lesions with nitinol stents in the superficial femoral and popliteal arteries: A midterm follow-up. Radiology. 2002;222:37–43
  167. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879–1888
  168. Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745–2749
  169. Krankenberg H, Schlüter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: The femoral artery stenting trial (FAST). Circulation. 2007;116:285–292
  170. Ferreira M, Lanziotti L, Monteiro M, et al. superficial femoral artery recanalization with self-expanding nitinol stents: Long-term follow up results. Eur J Vasc Endovasc Surg. 2007;34:702–708
  171. Dorrucci V. Treatment of superficial femoral artery occlusive disease. J Cardiovasc Surg. 2004;45:193–201
  172. Kedora J, Hohmann S, Garrett W, et al. Randomized comparison of percutaneous Viabahn stent grafts vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral arterial occlusive disease. J Vasc Surg. 2007;45:10–16
  173. Kazemi S, Tumuluri R, Allaqaband S, et al. Percutaneous revascularization of femoropopliteal arteries with self-expanding nitinol stents—Immediate success and one-year results. J Am Coll Cardiol. 2005;3(suppl 1):68A
  174. Alimi Ys, Hakam Z, Hartung O, et al. Efficacy of Viabahn in the treatment of severe superficial femoral artery lesions: Which factors influence long term patency?. Eur J Vasc Endovasc Surg. 2008;35:346–352
  175. McQuade K, Gable D, Hohman S, et al. Randomized comparison of ePTFE/nitinol self-expanding stent-graft vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease. J Vasc Surg. 2009;49:109–116
  176. Djelmani-Hani M, Nazir A, Taha M, et al. VIABAHN stent-graft for symptomatic recurrent in-stent restenosis of superficial femoral artery: Immediate success and long term patency. [Abstracts] MJ Cardiol. 2007;100(8):199L
  177. Ramaiah V, Gammon R, Kiesz S, et al. Midterm outcomes from the TALON Registry: Treating peripherals with SilverHawk: Outcomes collection. J Endovasc Ther. 2006;13:592–602
  178. Zeller T, Rastan A, Schwärzwalder U, et al. Percutaneous peripheral atherectomy of femoropopliteal stenoses using a new-generation device: Six-month results from a single-center experience. J Endovasc Ther. 2004;11:676–685
  179. Suri R, Wholey MH, Postoak D, et al. Distal embolic protection during femoropopliteal atherectomy. Catheter Cardiovasc Interv. 2006;67:417–422
  180. Zeller T, Rastan A, Sixt S, et al. Long-term results after directional atherectomy of femoropopliteal lesions. J Am Coll Cardiol. 2006;48:1573–1578
  181. Steinkamp HJ, Rademaker J, Wissgott C, et al. Percutaneous transluminal laser angioplasty versus balloon dilation for treatment of popliteal artery occlusions. J Endovasc Ther. 2002;9:882–888
  182. Scheinert D, Laird JR, Schöroder M, et al. Excimer laser-assisted recanalization of long, chronic superficial femoral artery occlusions. J Endovasc Ther. 2001;8:156–166
  183. Bosiers M, Peeters P, Elist FV, et al. excimer laser assisted angioplasty for critical limb ischemia (results of the LACI Belgium study). Eur J Vasc Endovasc Surg. 2005;29:613–619
  184. Laird J, Jaff MR, Biamino G, et al. Cryoplasty for the treatment of femoropopliteal arterial disease: Results of a prospective, multicenter registry. J Vasc Interv Radiol. 2005;16:1067–1073
  185. United States Food and Drug Administration. Center for Devices and Radiological Health. Class 1 Recall: Boston Scientific Flextome Cutting Balloon Systems. http://www.fda.gov/cdrh/recalls/recall-120705.htmlAccessed January 29, 2009
  186. Diehm N, Silvestro A, Do DD, et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. J Endovasc Ther. 2005;12:723–730
  187. Wolfram RM, Budinsky AC, Pokrajac B, et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: Five-year follow-up: Prospective randomized study. Radiology. 2006;240:878–884
  188. Wolfram RM, Budinsky AC, Pokrajac B, et al. Endovascular brachytherapy: Restenosis in de novo versus recurrent lesions of femoropopliteal artery: The Vienna experience. Radiology. 2005;236:338–342
  189. Therasse E, Donath D, Lesperance J, et al. External beam radiation to prevent restenosis after superficial femoral artery balloon angioplasty. Circulation. 2005;111:3310–3315
  190. Tepe G, Zeller T, Albretch T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689–699
  191. Rosenfield K, Schainfield R, Pieczek A, et al. Restenosis of endovascular stents from stent compression. J Am Coll Cardiol. 1997;29:328–338
  192. Schlager O, Dick P, Sabeti S, et al. Long-segment-SFA stenting-the dark sides: In-stent restenosis, clinical deterioration and stent fractures. J Endovasc Ther. 2005;12:676–684
  193. Veith FJ, Gupta SK, Ascer E, et al. Improved strategies for secondary operations on infrainguinal arteries. Ann Vasc Surg. 1990;4:85–93
  194. Ascer E, Collier P, Gupta SK, et al. Reoperation for polytetrafluoroethylene bypass failure: The importance of distal outflow site and operative technique in determining outcome. J Vasc Surg. 1987;5:298–310
  195. Veith FJ, Gupta SK, Wengerter KR, et al. Changing arteriosclerotic disease patterns and management strategies in lower-limb threatening ischemia. Ann Surg. 1990;212:412–414
  196. Bakal CW, Cynamon J, Sprayregan S. Infrapopliteal percutaneous transluminal angioplasty: What we know. Radiology. 1996;200:33–43
  197. Schwarten DE, Cutcliff WB. Arterial occlusive disease below the knee: Treatment with percutaneous transluminal angioplasty with low profile catheters and steerable guide wires. Radiology. 1988;169:71–74
  198. Hayes PD, Chokkalingam A, Jones R, et al. Arterial perforation during infrainguinal lower limb angioplasty does not worsen outcome: Results from 1409 patients. J Endovasc Ther. 2002;9:422–427
  199. Siablis D, Kraniotis P, Karnabatidis D, et al. Sirolimus-eluting versus bare stents for bailout after suboptimal infrapopliteal angioplasty for critical limb ischemia: 6-month angiographic results from a nonrandomized prospective single-center study. J Endovasc Ther. 2005;12:685–695
  200. Söder HK, Manninen HI, Jaakkola P, et al. Prospective trial of infrapopliteal artery balloon angioplasty for critical limb ischemia: Angiographic and clinical results. J Vasc Interv Radiol. 2000;11:1021–1031
  201. Tsetis D, Belli AM. The role of infrapopliteal angioplasty. Br J Radiol. 2004;77:1007–1015
  202. Scheinert D, Ulrich M, Scheinert S, et al. Comparison of sirolimus-eluting vs baremetal stents for the treatment of infrapopliteal obstructions. Eurointervention. 2006;2:169–174
  203. Bakal CW, Sprayregen S, Scheinbaum K, et al. Percutaneous transluminal angioplasty of the infrapopliteal arteries: Results in 53 patients. AJR Am J Roentgenol. 1990;154:171–174
  204. Sivananthan UM, Browne TF, Thorley PJ, et al. Percutaneous transluminal angioplasty of the tibial arteries. Br J Surg. 1994;81:1282–1285
  205. Varty K, Bolia A, Naylor AR, et al. Infrapopliteal percutaneous transluminal angioplasty: A safe and successful procedure. Eur J Vasc Endovasc Surg. 1995;9:341–345
  206. Dorros G, Jaff MR, Murphy KJ, et al. The acute outcome of tibioperoneal vessel angioplasty in 417 cases with claudication and critical limb ischemia. Catheter Cardiovasc Diagn. 1998;45:251–256
  207. Desgranges P, Kobeiter K, d'Audiffret A, et al. Acute occlusion of popliteal and/or tibial arteries: The value of percutaneous treatment. Eur J Vasc Endovasc Surg. 2000;20:138–145
  208. Hagino RT, Fujitani RM, Dawson DL, et al. Does infrapopliteal arterial runoff predict success for popliteal artery aneurysmorrhaphy?. Am J Surg. 1994;168(6):652–656
  209. Dorros G, Jaff MR, Dorros AM, et al. Tibioperoneal (outflow lesion) angioplasty can be used as primary treatment in 235 patients with critical limb ischemia: Five-year follow-up. Circulation. 2001;104:2057–2062
  210. Tsetis DK, Michalis LK, Rees MR, et al. Vibrational angioplasty in the treatment of chronic infrapopliteal arterial occlusions: Preliminary experience. J Endovasc Ther. 2002;9:889–895
  211. Rastogi S, Stavropoulos SW. Infrapopliteal angioplasty. Tech Vasc Interv Radiol. 2004;7:33–39
  212. Spinosa DJ, Leung DA, Matsumoto AH, et al. Percutaneous intentional extraluminal recanalization in patients with chronic critical limb ischemia. Radiology. 2004;232:499–507
  213. Nasr MK, McCarthy J, Hardman J, et al. The increasing role of percutaneous transluminal angioplasty in the primary management of critical limb ischaemia. Eur J Vasc Endovasc Surg. 2002;23:398–403
  214. Rand T, Basile A, Cejna M, et al. PTA versus carbofilm-coated stents in infrapopliteal arteries: Pilot study. Cardiovasc Interv Radiol. 2006;29:29–38
  215. Faglia E, Mantero M, Caminiti M, et al. Extensive use of peripheral angioplasty, particularly infrapopliteal, in the treatment of ischaemic diabetic foot ulcers: Clinical results of a multicentric study of 221 consecutive diabetic subjects. J Intern Med. 2002;252:225–232
  216. Faglia E, Dalla PL, Clerici G, et al. Peripheral angioplasty as the first-choice revascularization procedure in diabetic patients with critical limb ischemia: Prospective study of 993 consecutive patients hospitalized and followed between 1999 and 2003. Eur J Vasc Endovasc Surg. 2005;29:620–627
  217. Bull PG, Mendel H, Hold M, et al. Distal popliteal and tibioperoneal transluminal angioplasty: Long-term follow up. J Vasc Interv Radiol. 1992;3:45–53
  218. Brown KT, Moore Ed, Getrajdman GI, et al. Infrapopliteal angioplasty; long-term follow up. J Vasc Interv Radiol. 1993;4:139–144
  219. Tamura S, Sniderman KW, Beinart C, et al. Percutaneous transluminal angioplasty of the popliteal artery and its branches. Radiology. 1982;143:645–648
  220. Abdul Raouf A, Rouleau Y, Clement A, et al. Endoluminal angioplasty of the popliteal artery (review of 54 consecutive patients). Eur J Vasc Endovasc Surg. 2005;30:610–613
  221. Shalev Y, Fortsas MJ, Schmidt DH, et al. A modification of the peripheral angioplasty procedure to treat below-the-knee vascular disease: Initial success and late outcome in 97 patients. J Am Coll Cardiol. 1996;27:191A
  222. Grant AG, White CJ, Collins TJ, et al. Infrapopliteal drug-eluting stents for chronic limb ischemia. Circulation. 2006;114(Suppl II):II-820
  223. Feiring AJ, Wesolowski AA, Lade S. Primary stent supported angioplasty for treatment of below-knee critical limb ischemia and severe claudication: Early and one year outcomes. J Am Coll Cardiol. 2004;44:2307–2314
  224. Commeau P, Barragan P, Roguebert PO. Sirolimus for below the knee lesions: mid-term results of SiroBTK study. Catheter Cardiovasc Interv. 2006;68:793–798
  225. Bosiers M, Deloose K, Verbist J, et al. Percutaneous transluminal angioplasty for treatment of ‘“below-the-knee”’ critical limb ischemia: Early outcomes following the use of sirolimus-eluting stents. J Cardiovasc Surg. 2006;47:171–176
  226. Siablis D, Karnabatidis D, Katsanos K, et al. Sirolimus-eluting versus bare stents for bailout after suboptimal infrapopliteal angioplasty for critical limb ischemia: Enduring 1 year angiographic and clinical benefit. J Endovasc Ther. 2007;14(2):241–250
  227. Tepe G. Drug-eluting stents for infrainguinal occlusive disease: Progress and challenges. Semin Vasc Surg. 2006;19:102–108
  228. Bosiers M, Hart JP, Deloose K, et al. Endovascular therapy as the primary approach for limb salvage in patients with critical limb ischemia: Experience with 443 infrapopliteal procedures. Vascular. 2006;14:63–69
  229. Braithwaite BD, Davies B, Birch PA, et al. Management of acute leg ischemia in the elderly. Br J Surg. 1998;85:217e;220
  230. Blaisdell FW, Steele M, Allen RE. Management of acute lower extremity arterial ischemia due to embolism and thrombosis. Surgery. 1978;84:822–834
  231. Clason AE, Stonebridge PA, Duncan AJ, et al. Morbidity and mortality in acute lower limb ischaemia: A 5-year review. Eur J Vasc Surg. 1989;3:339–343
  232. Ouriel K. Endovascular techniques in the treatment of acute limb ischemia: Thrombolytic agents, trials, and percutaneous mechanical thrombectomy techniques. Semin Vasc Surg. 2003;16:270–279
  233. STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity (The STILE trial). Ann Surg. 1994;220:251–266
  234. Ouriel K, Shortell C, Deweese J, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg. 1994;19:1021–1030
  235. Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs (thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators). N Engl J Med. 1998;338:1105–1111
  236. Palfreyman SJ, Booth A, Michaels JA. A systematic review of intra-arterial thrombolytic therapy for lower-limb ischaemia. Eur J Vasc Endovasc Surg. 2000;19(2):143–157
  237. Berridge DC, Kessel D, Robertson I. Surgery versus thrombolysis for acute limb ischaemia: Initial management. Cochrane Database Syst Rev. 2002;3:CD002784
  238. Swischuk JL, Fox PF, Young K, et al. Transcatheter intraarterial infusion of rt-PA for acute lower limb ischemia: Results and complications. J Vasc Interv Radiol. 2001;12:423–430
  239. Nehler MR, Mueller RJ, McLafferty RB, et al. Outcome of catheter-directed thrombolysis for lower extremity arterial bypass occlusion. J Vasc Surg. 2003;37:72–78
  240. McNamara TO, Fischer JR. Thrombolysis of peripheral arterial and graft occlusions: Improved results using high-dose urokinase. AJR Am J Roentgenol. 1985;144:769–775
  241. Sullivan KL, Gardiner GA, Shapiro MJ, et al. Acceleration of thrombolysis with a high-dose transthrombus bolus technique. Radiology. 1989;173:805–808
  242. Valji K, Bookstein JJ, Roberts AC, et al. Pulse-spray pharmacomechanical thrombolysis of thrombosed hemodialysis access grafts: Long-term experience and comparison of original and current techniques. AJR Am J Roentgenol. 1995;164:1495–1500
  243. Armon MP, Yusuf SW, Whitaker SC, et al. Results of 100 cases of Puls-espray thrombolysis for acute and subacute leg ischaemia. Br J Surg. 1997;84:47–50
  244. Kandarpa K, Chopra PS, Aruny JE, et al. Intraarterial thrombolysis of lower extremity occlusions: Prospective, randomized comparison of forced periodic infusion and conventional slow continuous infusion. Radiology. 1993;188:861–867
  245. Braithwaite BD, Buckenham TM, Galland RB, et al. Prospective randomized trial of high-dose bolus versus low-dose tissue plasminogen activator infusion in the management of acute limb ischaemia (Thrombolysis Study Group). Br J Surg. 1997;84:646–650
  246. Plate G, Jansson I, Forssell C, et al. Thrombolysis for acute lower limb ischaemia—A prospective, randomised, multicenter study comparing two strategies. Eur J Vasc Endovasc Surg. 2006;31:651–660
  247. Silva JA, Ramee SR, Collins TJ, et al. Rheolytic thrombectomy in the treatment of acute limb-threatening ischemia: Immediate results and six-month follow-up of the multicenter AngioJet registry (Possis Peripheral AngioJet Study AngioJet Investigators). Catheter Cardiovasc Diagn. 1998;45:386–393
  248. Wagner HJ, Müller-Hülsbeck S, Pitton MB, et al. Rapid thrombectomy with a hydrodynamic catheter: Results from a prospective, multicenter trial. Radiology. 1997;205:675–681
  249. Ansel GM, Botti CF, Silver MJ. Treatment of acute limb ischemia with a percutaneous mechanical thrombectomy-based endovascular approach: 5-year limb salvage and survival results from a single center series. Catheter Cardiovasc Interv. 2008;72:325–330
  250. Ansel GM, George BS, Botti CF, et al. Rheolytic thrombectomy in the management of limb ischemia: 30-Day results from a multicenter registry. J Endovasc Ther. 2002;9:395–402
  251. Allie DE, Hebert CJ, Lirtzman MD, et al. Novel simultaneous combination chemical thrombolysis/rheolytic thrombectomy therapy for acute critical limb ischemia: The power-pulse spray technique. Catheter Cardiovasc Interv. 2004;63:512–522
  252. Shammas NW, Dippel EJ, Shammas G, et al. Dethrombosis of the lower extremity arteries using the power-pulse spray technique in patients with recent onset thrombotic occlusions: Results of the DETHROMBOSIS Registry. J Endovasc Ther. 2008;15:570–579
  253. Grossman PM, Mendelsohn F, Henry TD, et al. Results from a Phase II multicenter, double-blind placebo-controlled study of del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am Heart J. 2007;153:874–880
  254. Mann MJ, Whittemore AD, Donaldson MC, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial. Lancet. 1999;354:1493–1498
  255. Comerota AJ, Throm RC, Miller KA, et al. Naked plasmid DNA encoding fibroblast growth factor Type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: Preliminary results of a Phase I trial. J Vasc Surg. 2002;35:930–936
  256. Henry TD, Mendelsohn F, Comerota A, et al. Dose and regimen effects of intramuscular NV1FGF in patients with critical limb ischemia: A randomized, double-blind, placebo-controlled study. Eur Heart J. 2006;27(suppl 1):235
  257. Nikol S, Baumgartner I, Van Belle E, et al. TALISMAN 201 Investigators Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther. 2008;16:972–978
  258. Cooper LT, Hiatt WR, Creager MA, et al. Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. Vasc Med. 2001;6:235–239
  259. Lazarous DF, Unger EF, Epstein SE, et al. Basic fibroblast growth factor in patients with intermittent claudication: Results of a Phase I trial. J Am Coll Cardiol. 2000;36:1239–1244
  260. Lederman RJ, Mendelsohn FO, Anderson RD, et al. TRAFFIC Investigators Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): A randomised trial. Lancet. 2002;359:2053–2058
  261. Marui A, Tabata Y, Kojima S, et al. A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel: An initial report of the Phase I-IIa study. Circul J. 2007;71:1181–1186
  262. Matyas L, Schulte KL, Dormandy JA, et al. Arteriogenic gene therapy in patients with unreconstructable critical limb ischemia: A randomized, placebo-controlled clinical trial of adenovirus 5-delivered fibroblast growth factor-4. Hum Gene Ther. 2005;16:1202–1211
  263. Morishita R, Aoki M, Hashiya N, et al. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease erratum. Hypertension. 2006;48:e7;2004;44:203-9
  264. Powell RJ, Simons M, Mendelsohn FO, et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation. 2008;118:58–65
  265. Rajagopalan S, Olin J, Deitcher S, et al. Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: Phase I dose-escalation experience. Circulation. 2007;115:1234–1243
  266. Rajagopalan S, Mohler ER, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A Phase II randomized, double-blind, con-trolled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003;108:1933–1938
  267. Isner JM, Pieczek A, Schainfeld R, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet. 1996;348:370–374
  268. Isner JM, Baumgartner I, Rauh G, et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: Preliminary clinical results. J Vasc Surg. 1998;28:964–973
  269. van Royen N, Schirmer SH, Atasever B, et al. START Trial (A pilot study on stimulation of ARTteriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease). Circulation. 2005;112:1040–1046
  270. Clouse WD, Hallett JW, Schaff HV, et al. Improved prognosis of thoracic aortic aneurysms: A population based study. J Am Med Assoc. 1998;280:1926–1929
  271. Katzen BY, Dake MD, MacLean AA, et al. Endovascular repair of abdominal and thoracic aortic aneurysms. Circulation. 2005;112:1663–1675
  272. Coady MA, Rizzo JA, Hammond GL, et al. Surgical intervention criteria for thoracic aortic aneurysms: A study of growth rates and complications. Ann Thorac Surg. 1999;67:1922–1926
  273. Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: Simple prediction based on size. Ann Thorac Surg. 2002;73:17–27
  274. Bavaria JE, Appoo JJ, Makaroun MS, et al. Endovascular stent grafting versus open surgical repair of descending thoracic aortic aneurysms in low-risk patients: A multicenter comparative trial. J Thorac Cardiovasc Surg. 2007;133:369–377
  275. Hodges TC, Cronenwett J. Abdominal aortic and iliac artery aneurysms: Clinical presentation, natural history, and indications for intervention. In:  Perler BA,  Becker GJ editor. Vascular Intervention: A Clinical Approach. New York, NY: Thieme; 1998;p. 339–350
  276. Kaufman JA, Geller SC, Brewster DC, et al. Endovascular repair of abdominal aortic aneurysms: Current status and future directions. AJR Am J Roentgenol. 2000;175:289–302
  277. Nevitt MP, Ballard DJ, Hallett JW. Prognosis of abdominal aortic aneurysms (A population-based study). N Engl J Med. 1989;321:1009–1014
  278. Hallett JW. Management of abdominal aortic aneurysms. Mayo Clin Proc. 2000;75:395–399
  279. Hollier LH, Taylor LM, Ochsner J. Recommended indications for operative treatment of abdominal aortic aneurysms: Report of a subcommittee of the Joint Council of the Society for Vascular Surgery and the International Society for Cardiovascular Surgery. J Vasc Surg. 1992;15:1046–1056
  280. Hallett JW, Marshall DM, Petterson TM, et al. Graft-related complications after abdominal aortic aneurysm repair: Reassurance from a 36-year population-based experience. J Vasc Surg. 1997;25:277–286
  281. Johnston KW. Nonruptured abdominal aortic aneurysm: Six-year follow-up results from the multicenter prospective Canadian aneurysm study (Canadian Society for Vascular Surgery Aneurysm Study Group). J Vasc Surg. 1994;20:163–170
  282. Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graft implantation for abdominal aortic aneurysms. Ann Vasc Surg. 1991;5:491–499
  283. Longo GM, Eskandari MK. Overview of success of EVAR: Progress to date. Semin Vasc Surg. 2004;17:307–313
  284. Zarins CK, White RA, Moll FL, et al. The AneuRx stent-graft: Four-year results and worldwide experience 2000. J Vasc Surg. 2001;33:S135–S145
  285. Buth J, van Marrewijk CJ, Harris PL, et al. Outcome of endovascular abdominal aortic aneurysm repair in patients with conditions considered unfit for an open procedure: A report on the Eurostar experience. J Vasc Surg. 2002;35:211–221
  286. Leurs LJ, Bell R, Degrieck Y, et al. Endovascular treatment of thoracic aortic diseases: Combined experience from the Eurostar and UK thoracic endograft registries. J Vasc Surg. 2004;40:670–680
  287. Greenhalgh RM, Allison DJ, Bell PR, et al. Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: Randomized controlled trial. Lancet. 2004;364:843–848
  288. Greenhalgh RM, Allison DJ, Bell PR, et al. Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurysm (EVAR trial 2): Randomized controlled trial. Lancet. 2005;365:2187–2192
  289. Prinssen M, Verhoeven EL, Buth J, et al. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. N Engl J Med. 2004;351:1607–1618
  290. Schermerhorn ML, O'Malley AJ, Jhaveri R, et al. Endovascular vs. open repair of abdominal aortic aneurysms in the Medicare population. N Engl J Med. 2008;358:464–474
  291. Hallett JW, Marshall DM, Petterson TM, et al. Graft-related complications after abdominal aortic aneurysm repair: Reassurance from a 36-year population-based experience. J Vasc Surg. 1997;25:277–284
  292. Biancari F, Ylonen K, Anttila V, et al. Durability of open repair of infrarenal abdominal aortic aneurysm: A 15-year follow-up study. J Vasc Surg. 2002;35:87–93
  293. Siami FS Lifeline Registry of EVAR Publications Committee. Lifeline registry of endovascular aneurysm repair: Long-term primary outcome measures. J Vasc Surg. 2005;42:1–10
  294. May J, White GH, Waugh R, et al. Improved survival after endoluminal repair with second-generation prostheses compared with open repair in the treatment of abdominal aortic aneurysms: A 5-year concurrent comparison using life table method. J Vasc Surg. 2001;33(2):S21–S26(suppl)
  295. Zarins CK AneuRx Clinical Investigators. The US AneuRx Clinical Trial: 6-year clinical update 2002. J Vasc Surg. 2003;37:904–908
  296. Harris PL, Buth J. An update on the important findings from the Eurostar EVAR registry. Vascular. 2004;12:33–38
  297. Kibbe MR, Matsumura JS. The Excluder Investigators: The Gore Excluder US Multi-Center Trial: Analysis of adverse events at 2 years. Semin Vasc Surg. 2003;16:144–150
  298. Matsumura JS, Brewster DC, Makaroun MS, et al. A multicenter controlled clinical trial of open versus endovascular treatment of abdominal aortic aneurysm. J Vasc Surg. 2003;37:262–271
  299. Moore WS. The Guidant Ancure bifurcation endograft: Five-year follow-up. Semin Vasc Surg. 2003;16:139–143
  300. Moore WS, Matsumura JS, Makaroun MS, et al. Five-year interim comparison of the Guidant bifurcated endograft with open repair of abdominal aortic aneurysm. J Vasc Surg. 2003;38:46–55
  301. Greenberg R. The Zenith Investigators: The zenith AAA endovascular graft for abdominal aortic aneurysms: Clinical update. Semin Vasc Surg. 2003;16:151–157
  302. Sternbergh WC, Money SR, Greenberg RK, et al. Influence of endograft oversizing on device migration, endoleak, aneurysm shrinkage, and aortic neck dilation: Results from the Zenith Multicenter Trial. J Vasc Surg. 2004;39:20–26
  303. Bertges DJ, Chow K, Wyers MC, et al. Abdominal aortic aneurysm size regression after endovascular repair is endograft dependent. J Vasc Surg. 2003;37:716–723
  304. Sachdev U, Baril DT, Ellozy SH, et al. Management of aneurysms involving branches of the celiac and superior mesenteric arteries: A comparison of surgical and endovascular therapy. J Vasc Surg. 2006;44:718–724
  305. Abbas MA, Fowl RJ, Stone WN, et al. Hepatic artery aneurysm: Factors that predict complications. J Vasc Surg. 2003;38:41–45
  306. Berceli SA. Hepatic and splenic artery aneurysms. Semin Vasc Surg. 2005;18:196–201
  307. Nachbur BH, Inderbitzi RG, Bar W. Isolated iliac aneurysms. Eur J Vasc Surg. 1991;5:375–381Richardson JW, Greenfield LJ
  308. Richardson JW, Greenfield LJ. Natural history and management of iliac aneurysms. J Vasc Surg. 1988;8:165–171
  309. Scheinert D, Schroder M, Steinkamp H, et al. Treatment of iliac artery aneurysms by percutaneous implantation of stent grafts. Circulation. 2000;102:III-253–III-258
  310. Sahgal A, Veith F, Lipsitz E, et al. Diameter changes in isolated iliac artery aneurysms 1 to 6 years after endovascular graft repair. J Vasc Surg. 2001;33:289–295
  311. Huand Y, Gloviczki P, Duncan AA, et al. Common iliac artery aneurysm: Expansion rate and results of open surgical and endovascular repair. J Vasc Surg. 2008;47:1203–1211
  312. Pitoulias GA, Donas KP, Schulte S, et al. Isolated iliac artery aneurysms: Endovascular versus open elective repair. J Vasc Surg. 2007;46:648–654
  313. Trickett JP, Scott RAP, Tilney HS. Screening and management of asymptomatic popliteal aneurysms. J Med Screen. 2002;9:92–93
  314. Curi MA, Geraghty PJ, Merion OA, et al. Mid-term outcomes of endovascular popliteal artery aneurysm repair. J Vasc Surg. 2007;45:505–510
  315. Thompson MM, Sayers RD. Arterial aneurysms. In: Companion to Specialist Surgical Practice, Vol VII (Arterial Surgery). London: WB Saunders; 1998;
  316. Dawson I, Sie RB, van Bockel JH. Atherosclerotic popliteal aneurysm. Br J Surg. 1997;84:293–299
  317. Michaels JA, Galland RB. Management of asymptomatic popliteal aneurysms: The use of a markov decision tree to determine the criteria for a conservative approach. Eur J Vasc Surg. 1993;7:136–143
  318. Tielliu IFJ, Verhoeven ELG, Prins TR, et al. Treatment of popliteal artery aneurysms with the Hemobahn stent-graft. J Endovasc Ther. 2003;10:111–116
  319. Antonello M, Frigatti P, Battocchio P, et al. Open repair versus endovascular treatment for asymptomatic popliteal artery aneurysm: Results of a prospective randomized study. J Vasc Surg. 2005;42:185–193
  320. Cina CS, Moor R, Maggisano R, et al. Endovascular repair of popliteal artery aneurysms with anaconda limbs: Technique and early results. Catheter Cardiovasc Int. 2008;72:716–724
  321. Siauw R, Koh EH, Walker SR. Endovascular repair of polyteal artery aneurysms: Techniques, current evidence and recent experience. Aust NZ J Surg. 2006;76:505–511
  322. Chang R, Horne MK, Mayo DJ, et al. Pulse-spray treatment of subclavian and jugular venous thrombi with recombinant tissue plasminogen activator. J Vasc Interv Radiol. 1996;7:845–851
  323. Adelman MA, Stone DH, Riles TS, et al. A multidisciplinary approach to the treatment of Paget-Schroetter syndrome. Ann Vasc Surg. 1997;11:149–154
  324. Kee ST, Kinoshita L, Razavi MK, et al. Superior vena cava syndrome: Treatment with catheter-directed thrombolysis and endovascular stent placement. Radiology. 1998;206:187–193
  325. Angle N, Gelabert HA, Farooq MM, et al. Safety and efficacy of early surgical decompression of the thoracic outlet outlet for Paget-Schroetter syndrome. Ann Vasc Surg. 2001;15:37–42
  326. Machleder HI. Evaluation of a new treatment strategy for Paget-Schroetter syndrome: Spontaneous thrombosis of the axillary-subclavian vein. J Vasc Surg. 1993;17:305–315
  327. Molina JE. Need for emergency treatment in subclavian vein effort thrombosis. J Am Coll Surg. 1995;181:414–420
  328. Urschel HC, Razzuk MA, Paget-Schroetter . Syndrome: What is the best management?. Ann Thorac Surg. 2000;69:1663–1668
  329. Kreienberg PB, Chang BB, Darling RC, et al. Long-term results in patients treated with thrombolysis, thoracic inlet decompression, and subclavian vein stenting for Paget-Schroetter syndrome. J Vasc Surg. 2001;33(suppl):S100–S105
  330. Lokanathan R, Salvian AJ, Chen JC, et al. Outcome after thrombolysis and selective thoracic outlet decompression for primary axillary vein thrombosis. J Vasc Surg. 2001;33:783–788
  331. Heit JA, Melton LJ, Lohse CM, et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc. 2001;76:1102–1110
  332. Fowkes FJ, Price JF, Fowkes FG. Incidence of diagnosed deep vein thrombosis in the general population: Systematic review. Eur J Vasc Endovasc Surg. 2003;25:1–5
  333. Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: Incidence and risk factors. Arch Intern Med. 2000;160:769–774
  334. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A population-based cohort study. Arch Intern Med. 2000;160:761–768
  335. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism the Worcester DVT study. Arch Intern Med. 1991;151:933–938
  336. Gould MK, Dembitzer AD, Doyle RL, et al. Low molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis (A meta-analysis of randomized, controlled trials). Ann Intern Med. 1999;130:800–809
  337. Hirsh J, Siragusa S, Cosmi B, et al. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Haemost. 1995;74:360–363
  338. van Den Belt AG, Prins MH, Lensing AW, et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2000;CD001100
  339. Chong BH, Brighton TA, Baker RI, et al. ASTH DVT Study Group Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis. J Thromb Thrombolysis. 2005;19:173–181
  340. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism (Duration of Anticoagulation Trial Study Group). N Engl J Med. 1995;332:1661–1665
  341. Pinede L, Ninet J, Duhaut P, et al. Investigators of the Dure'e Optimale du Traitement AntiVitamines K” (DOTA VK) Study Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation. 2001;103:2453–2460
  342. Ridker PM, Goldhaber SZ, Danielson E, et al. PREVENT Investigators Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425–1434
  343. Agnelli G, Prandoni P, Becattini C, et al. Warfarin Optimal Duration Italian Trial Investigators Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med. 2003;139:19–25
  344. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1–7
  345. Akesson H, Brudin L, Dahlström JA, et al. Venous function assessed during a 5-year period after acute Ilio-femoral venous thrombosis treated with anticoagulation. Eur J Vasc Surg. 1990;4:43–48
  346. Saarinen J, Sisto T, Laurikka J, et al. Late sequelae of acute deep venous thrombosis: Evaluation five to ten years later. Phlebology. 1995;10:106–109
  347. Janssen MC, Haenen JH, van Asten WM, et al. Clinical and hemodynamic sequelae of deep venous thrombosis: Retrospective evaluation after 7-13 years. Clin Sci. 1997;93:7–12
  348. Brandjes DPM, Büller HR, Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet. 1997;349:759–762
  349. Elliot MS, Immelman EJ, Jeffery P, et al. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: An interim report of a prospective trial. Br J Surg. 1979;66:838–843
  350. Arnesen H, Høiseth A, Ly B. Streptokinase or heparin in the treatment of deep vein thrombosis: Follow-up results of a prospective study. Acta Med Scand. 1982;211:65–68
  351. Meissner MH, Manzo RA, Bergelin RO, et al. Deep venous insufficiency: The relationship between lysis and subsequent reflux. J Vasc Surg. 1993;18:596–605discussion, 606-8
  352. Elsharawy M, Elzayat E. Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis (A randomised clinical trial). Eur J Vasc Endovasc Surg. 2002;24:209–214
  353. Mewissen MW, Seabrook GR, Meissner MH, et al. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: Report of a national multicenter registry. Radiology. 1999;211:39–49
  354. Bjarnason H, Kruse JR, Asinger DA, et al. Iliofemoral deep venous thrombosis: Safety and efficacy outcome during 5 years of catheter-directed thrombolytic therapy. J Vasc Interv Radiol. 1997;8:405–418
  355. Semba CP, Dake MD. Iliofemoral deep venous thrombosis: Aggressive therapy with catheter-directed thrombolysis. Radiology. 1994;191:487–494
  356. Razavi MK, Wong H, Kee ST, et al. Initial clinical results of tenecteplase (TNK) in catheter-directed thrombolytic therapy. J Endovasc Ther. 2002;9:593–598
  357. Raju S, Fountain T, McPherson SH. Catheter-directed thrombolysis for deep venous thrombosis. J Miss State Med Assoc. 1998;39:81–84
  358. Castaneda F, Li R, Young K, et al. Catheter directed thrombolysis in deep venous thrombosis with use of reteplase: Immediate results and complications from a pilot study. J Vasc Interv Radiol. 2002;13:577–580
  359. Horne MK, Mayo DJ, Cannon RO, et al. Intraclot recombinant tissue plasminogen activator in the treatment of deep venous thrombosis of the lower and upper extremities. Am J Med. 2000;108:251–255
  360. Ouriel K, Katzen B, Mewissen M, et al. Reteplase in the treatment of peripheral arterial and venous occlusions: A pilot study. J Vasc Interv Radiol. 2000;11:849–854
  361. Sugimoto K, Hofmann LV, Razavi MK, et al. The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions. J Vasc Surg. 2003;37:512–517
  362. Acharya G, Singh K, Hansen JB, et al. Catheter-directed thrombolysis for the management of postpartum deep venous thrombosis. Acta Obstet Gynecol Scand. 2005;84:155–158
  363. Ogawa T, Hoshino S, Midorikawa H, et al. Intermittent pneumatic compression of the foot and calf improves the outcome of catheter-directed thrombolysis using low-dose urokinase in patients with acute proximal venous thrombosis of the leg. J Vasc Surg. 2005;42:940–944
  364. Laiho MK, Oinonen A, Sugano N, et al. Preservation of venous valve function after catheter-directed and systemic thrombolysis for deep venous thrombosis. Eur J Vasc Endovasc Surg. 2004;28:391–396
  365. Sillesen H, Just S, Jørgensen M, et al. Catheter directed thrombolysis for treatment of Ilio-femoral deep venous thrombosis is durable, preserves venous valve function and may prevent chronic venous insufficiency. Eur J Vasc Endovasc Surg. 2005;30:556–562
  366. Grunwald MR, Hofmann LV. Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis. J Vasc Interv Radiol. 2004;15:347–352
  367. Semba CP, Razavi MK, Kee ST, et al. Thrombolysis for lower extremity deep venous thrombosis. Tech Vasc Interv Radiol. 2004;7:68–78
  368. May R, Thurner J. A vascular spur in the vena iliaca communis sinistral as a cause of predominantly left-sided thrombosis of the pelvic veins. Z Kreislaufforsch. 1956;45:912–922
  369. May R, Thurner J. The cause of the predominantly sinistral occurrence of thrombosis of the pelvic veins. Angiology. 1957;8:419–427
  370. Kim JY, Choi D, Guk Ko Y, et al. Percutaneous treatment of deep vein thrombosis in May–Thurner syndrome. Cardiovasc Interv Radiol. 2006;29:571–575
  371. Husmann MJ, Heller G, Kalka C, et al. Stenting of common iliac vein obstructions combined with regional thrombolysis and thrombectomy in acute deep vein thrombosis. Eur J Vasc Endovasc Surg. 2007;34:87–91
  372. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901–907
  373. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631–639
  374. Schulman S, Granqvist S, Holmström M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism (The Duration of Anticoagulation Trial Study Group). N Engl J Med. 1997;336:393–398
  375. Stein PD, Kayali F, Olson RE. Twenty-one year trends in the use of inferior vena cava filters. Arch Intern Med. 2004;164:1541–1545
  376. Hann CL, Streiff MB. The role of vena caval filters in the management of venous thromboembolism. Blood Rev. 2005;19:179–202
  377. Decousus H, Leizorovicz A, Parent F, et al. The PREPIC Study Group A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis (the prévention du risque d'embolie pulmonaire par interruption randomized study). N Engl J Med. 1998;338:409–415
  378. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: The PREPIC (prevention du risque d'embolie pulmonaire par interruption cave) randomized study. Circulation. 2005;112:416–422
  379. White RH, Zhou H, Kim J, et al. A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism. Arch Intern Med. 2000;160:2033–2041
  380. Horattas MC, Wright DJ, Fenton AH, et al. Changing concepts of deep venous thrombosis of the upper extremity—Report of a series and review of the literature. Surgery. 1988;104:561–567
  381. Kammen BF, Soulen MC. Phlegmasia cerulea dolens of the upper extremity. J Vasc Interv Radiol. 1995;6:283–286
  382. Bolitho DG, Elwood ET, Roberts F. Phlegmasia cerulea dolens of the upper extremity. Ann Plast Surg. 2000;45:644–646
  383. Hingorani A, Ascher E, Lorenson E, et al. Upper extremity deep venous thrombosis and its impact on morbidity and mortality rates in a hospital-based population. J Vasc Surg. 1997;26:853–860
  384. Monreal M, Raventos A, Lerma R, et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines—A prospective study. Thromb Haemost. 1994;72:548–550
  385. Roos DB. Congenital anomalies associated with thoracic outlet syndrome: Anatomy, symptoms, diagnosis, and treatment. Am J Surg. 1976;132:771–778
  386. AbuRahma AF, Robinson PA. Effort subclavian vein thrombosis: Evolution of management. J Endovasc Ther. 2000;7:302–308
  387. Rutherford RB, Hurlbert SN. Primary subclavian-axillary vein thrombosis: Consensus and commentary. Cardiovasc Surg. 1996;4:420–423
  388. Yim CD, Sane SS, Bjarnason H. Superior vena cava stenting. Radiol Clin North Am. 2000;38:409–424
  389. Schindler N, Vogelzang RL. Superior vena cava syndrome: Experience with endovascular stents and surgical therapy. Surg Clin North Am. 1999;79:683–694
  390. Stockx L, Raat H, Donck J, et al. Repositioning and leaving in situ the central venous catheter during percutaneous treatment of associated superior vena cava syndrome: A report of eight cases. Cardiovasc Interv Radiol. 1999;22:224–226
  391. Slonim SM, Semba CP, Sze DY, et al. Placement of SVC stents over pacemaker wires for the treatment of SVC syndrome. J Vasc Interv Radiol. 2000;11:215–219
  392. Bechtold RE, Wolfman NT, Karstaedt N, et al. Superior vena caval obstruction: Detection using CT. Radiology. 1985;157:485–487
  393. Kim HJ, Kim HS, Chung SH. Diagnosis of superior vena cava syndrome: Importance of collateral vessels. AJR Am J Roentgenol. 1993;161:539–542
  394. Eren S, Karaman A, Okur A. The superior vena cava syndrome caused by malignant disease (Imaging with multi-detector row CT). Eur J Radiol. 2006;59:93–103
  395. Lin J, Zhou KR, Chen ZW, et al. Vena cava 3D contrast-enhanced MR venography: A pictorial review. Cardiovasc Interv Radiol. 2005;28:795–805
  396. Thornton MJ, Ryan R, Varghese JC, et al. A threedimensional gadolinium-enhanced MR venography technique for imaging central veins. AJR Am J Roentgenol. 1999;173:999–1003
  397. Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: Clinical characteristics and evolving etiology. Medicine. 2006;85:37–42
  398. Markman M. Diagnosis and management of superior vena cava syndrome. Cleve Clin J Med. 1999;66:59–61
  399. Charnsangavej C, Carrasco C, Wallace S, et al. Stenosis of the vena cava: Preliminary assessment of treatment with expandable metallic stent. Radiology. 1986;161:295–298
  400. Mathias K, Jäger H, Willaschek J, et al. Interventional radiology in central venous obstructions (Dilatation–stent implantation–thrombolysis). Radiologe. 1998;38:606–613
  401. Sunder SK, Ekong EA, Sivalingam K, et al. Superior vena cava thrombosis due to pacing electrodes: Successful treatment with combined thrombolysis and angioplasty. Am Heart J. 1992;123:790–792
  402. Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: A systematic review. Clin Oncol. 2002;14:338–351
  403. Ostler PJ, Clarke DP, Watkinson AF, et al. Superior vena cava obstruction: A modern management strategy. Clin Oncol. 1997;9:83–89
  404. Smayra T, Otal P, Chabbert V, et al. Long-term results of endovascular stent placement in the superior caval venous system. Cardiovasc Interv Radiol. 2001;24:388–394
  405. Nicholson AA, Ettles DF, Arnold A, et al. Treatment of malignant superior vena cava obstruction: Metal stents or radiation therapy. J Vasc Interv Radiol. 1997;8:781–788
  406. Crowe MT, Davies CH, Gaines PA. Percutaneous management of superior vena cava occlusions. Cardiovasc Interv Radiol. 1995;18:367–372
  407. Rizvi AZ, Kalra M, Bjarnason H, et al. Benign superior vena cava syndrome: Stenting is now the first line of treatment. J Vasc Surg. 2008;47:372–380
  408. Lanciego C, Chacón JL, Julián A, et al. Stenting as first option for endovascular treatment of malignant superior vena cava syndrome. AJR Am J Roentgenol. 2001;177:585–593
  409. Bissett D, Kaye SB, Baxter G, et al. Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy. Clin Oncol. 1996;8:247–249
  410. Barakat K, Robinson NM, Spurrell RA. Transvenous pacing lead-induced thrombosis: A series of cases with a review of the literature. Cardiology. 2000;93:142–148
  411. Qanadli SD, El Hajjam M, Mignon F, et al. Subacute and chronic benign superior vena cava obstructions: Endovascular treatment with self-expanding metallic stents. AJR Am J Roentgenol. 1999;173:159–164
  412. Edwards RD, Jackson JE. Case report: Superior vena caval obstruction treated by thrombolysis, mechanical thrombectomy and metallic stents. Clin Radiol. 1993;48:215–217

 The authors have no conflicts of interest to disclose.

PII: S0146-2806(09)00074-7

doi: 10.1016/j.cpcardiol.2009.05.001

Current Problems in Cardiology
Volume 34, Issue 9 , Pages 359-476 , September 2009

Article Tools

* Image Usage & Resolution